← GLP-1 receptor agonists × cardiovascular events

SynthesisEuropean journal of medical research2025

Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis.

Rui Wu et al.PubMed ↗Full text ↗Publisher ↗

  • Semaglutidelooks good hereLower atrial fibrillation, lower acute myocardial infarction, lower angina pectoris.Randomised, large.

What the trial testedrandomised · 22,937 people · 2025

Randomised vs controls

Lowered atrial fibrillation

−21%−37% to −1%

semaglutide vs controls

Bigger than 5 in 10 for cardiovascular events

As reported

RR 0.79, 95% CI 0.63–0.99

Randomised vs controls

Lowered acute myocardial infarction

−28%−40% to −15%

semaglutide vs controls

Bigger than 7 in 10 for cardiovascular events

As reported

RR 0.72, 95% CI 0.60–0.85

Randomised vs controls

Lowered angina pectoris

−23%−39% to −2%

semaglutide vs controls

Bigger than 5 in 10 for cardiovascular events

As reported

RR 0.77, 95% CI 0.61–0.98

Range includes no effect

No clear effect on sinus node dysfunction

−57%−81% to +0%

semaglutide vs controls

Bigger than 9 in 10 for cardiovascular events

As reported

RR 0.43, 95% CI 0.19–1.00

Who was studied, and how

22,937people with arrhythmia, in this paper

The trial randomly assignedassigned by chance

semaglutide
controls

Lowered atrial fibrillation−21%

Lowered acute myocardial infarction−28%

Lowered angina pectoris−23%

randomised

the abstract, start to end

… the risk of atrial fibrillation (AF) (RR 0.79, 95% CI 0.63-0.99), sinus node dysfunction (RR 0.43, 95% CI 0.19-1.00), acute myocardial infarction (RR 0.72, 95% CI 0.60-0.85), and angina pectoris (RR 0.77, 95% CI 0.61-0.98).

← favours treatmentfavours comparator →
could be chance
Atrial fibrillation (AF)semaglutide vs controls
RR 0.790.63–0.99
Sinus node dysfunctionsemaglutide vs controls
RR 0.430.19–1.00
Acute myocardial infarctionsemaglutide vs controls
RR 0.720.60–0.85
Angina pectorissemaglutide vs controls
RR 0.770.61–0.98
GLP-1 receptor agonistsCardiovascular events

GLP-1 receptor agonists × cardiovascular eventshelps?mixed

unlikelylikely
0.50not counted
← favours treatmentfavours comparator →
more certainless certain
1 / 6

2 papers cite it

2025
2026
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 40890879